Hi Macik,I've emailed the administrators a couple times for an update. Have yet to receive a reply so I dont think it's very high on the priority list.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling